Dicot Pharma (DICOT) Stock Overview
Engages in the development of pharmaceutical products in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DICOT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dicot Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.59 |
| 52 Week High | SEK 0.90 |
| 52 Week Low | SEK 0.15 |
| Beta | 1.68 |
| 1 Month Change | -4.08% |
| 3 Month Change | 112.66% |
| 1 Year Change | 102.76% |
| 3 Year Change | 17.60% |
| 5 Year Change | -56.61% |
| Change since IPO | -93.16% |
Recent News & Updates
Recent updates
We're Hopeful That Dicot Pharma (STO:DICOT) Will Use Its Cash Wisely
Jun 13
Dicot Pharma (STO:DICOT) Is In A Good Position To Deliver On Growth Plans
Feb 26Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation
Nov 12We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate
Apr 09We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully
Dec 23Shareholder Returns
| DICOT | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 9.1% | 3.9% | 1.0% |
| 1Y | 102.8% | -5.5% | -4.0% |
Return vs Industry: DICOT exceeded the Swedish Pharmaceuticals industry which returned -4.5% over the past year.
Return vs Market: DICOT exceeded the Swedish Market which returned -0.6% over the past year.
Price Volatility
| DICOT volatility | |
|---|---|
| DICOT Average Weekly Movement | 14.2% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: DICOT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: DICOT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Elin Trampe | www.dicotpharma.com |
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It is developing LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024.
Dicot Pharma AB Fundamentals Summary
| DICOT fundamental statistics | |
|---|---|
| Market cap | SEK 1.18b |
| Earnings (TTM) | -SEK 67.00m |
| Revenue (TTM) | n/a |
Is DICOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DICOT income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 67.00m |
| Earnings | -SEK 67.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DICOT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 04:43 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dicot Pharma AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.